Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.

Abstract:

:Imatinib mesilate (Glivec), Novartis Pharmaceuticals) is a novel therapy for the treatment of chronic myeloid leukaemia (CML). We evaluated the cost-effectiveness of imatinib (600 mg daily) when used for the treatment of patients in advanced stages of CML (accelerated phase and blast crisis) against conventional therapies of combination chemotherapy (DAT) and palliative care in hospital or at home. A Markov model simulated the transitions of hypothetical patient cohorts and outcomes were modelled for 5 years from the start of treatment. Costs were estimated from the perspective of the UK National Health Service. Over 5 years, a patient in accelerated phase will, on average, accrue an additional 2.09 QALYs with imatinib compared to conventional therapies, while patients in blast crisis will accrue an additional 0.58 quality-adjusted life-years (QALYs) with imatinib compared to conventional therapies. The costs per additional QALY gained from treatment with imatinib compared with conventional therapies were pound 29344 (accelerated phase) and pound 42239 (blast crisis). The results were particularly sensitive to the price of imatinib, improvements in quality of life, and the duration of haematological responses. We conclude that treatment of CML with imatinib confers considerably greater survival and quality of life than conventional treatments but at a cost.

journal_name

Br J Cancer

authors

Gordois A,Scuffham P,Warren E,Ward S

doi

10.1038/sj.bjc.6601151

subject

Has Abstract

pub_date

2003-08-18 00:00:00

pages

634-40

issue

4

eissn

0007-0920

issn

1532-1827

pii

6601151

journal_volume

89

pub_type

杂志文章
  • Chlamydiae and Mycoplasma infections in pulmonary MALT lymphoma.

    abstract::Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci were detected at low frequencies (<20%) among 69 pulmonary mucosa-associated lymphoid tissue (MALT) lymphomas, 30 other lymphoproliferative disorders (LPD) and 44 non-LPD. The incidence of individual Chlamydiae was generally higher in MALT lymphoma tha...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6603981

    authors: Chanudet E,Adam P,Nicholson AG,Wotherspoon AC,Ranaldi R,Goteri G,Pileri SA,Ye H,Müller-Hermelink HK,Du MQ

    更新日期:2007-10-08 00:00:00

  • High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.

    abstract::From 1984 to 1989, 63 patients with diffuse, malignant mesothelioma of the pleura were treated with 4-8 courses of high-dose methotrexate (HDMTX, 3 g total dose) and citrovorum factor rescue. There were 61 male and two female patients of median age 60 years. CT scan was performed before and after treatment and used fo...

    journal_title:British journal of cancer

    pub_type: 临床试验,杂志文章

    doi:10.1038/bjc.1992.200

    authors: Solheim OP,Saeter G,Finnanger AM,Stenwig AE

    更新日期:1992-06-01 00:00:00

  • Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus.

    abstract::The aim of this paper was to provide epidemiological evidence to support the notion that cervical intraepithelial neoplasia (CIN) without human papillomavirus (HPV) is a true entity. If a diagnosis of HPV-negative cervical neoplasia is erroneous, one would not expect there to be any differences in risk factors between...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1996.146

    authors: Burger MP,Hollema H,Pieters WJ,Schröder FP,Quint WG

    更新日期:1996-03-01 00:00:00

  • A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma.

    abstract::A chelating derivative of alpha-melanocyte stimulating hormone (MSH) has been synthesised, in which two molecules of the hormone are cross-linked by diethylenetriamine pentaacetic acid (DTPA). This compound, bisMSH-DTPA, was equipotent with MSH in an in vitro tyrosinase assay with Cloudman S91 melanoma cells. When DBA...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1990.409

    authors: Bard DR,Knight CG,Page-Thomas DP

    更新日期:1990-12-01 00:00:00

  • Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women.

    abstract:BACKGROUND:In 2006, the National Health Service Bowel Cancer Screening Programme in England (NHSBCSP) began offering routine population-based biennial faecal occult blood testing (FOBt) at ages 60-69. There is, however, limited information on how characteristics of individuals affect participation and outcomes of scree...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.2015.69

    authors: Blanks RG,Benson VS,Alison R,Brown A,Reeves GK,Beral V,Patnick J,Green J

    更新日期:2015-04-28 00:00:00

  • Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.

    abstract:BACKGROUND:Complete tumour response (pCR) to neo-adjuvant chemo-radiotherapy for rectal cancer is associated with a reduction in local recurrence and improved disease-free and overall survival, but is achieved in only 20-30% of patients. Drug repurposing for anti-cancer treatments is gaining momentum, but the potential...

    journal_title:British journal of cancer

    pub_type: 杂志文章,meta分析

    doi:10.1038/bjc.2017.175

    authors: Gash KJ,Chambers AC,Cotton DE,Williams AC,Thomas MG

    更新日期:2017-07-11 00:00:00

  • Influence of misonidazole on the incidence of radiation-induced intestinal tumours in mice.

    abstract::C57BL mice were given local irradiation to 2 cm2 of the lower abdomen in the dose range 16--24 Gy. There were some early deaths, but mice dying between 50--240 days predominantly developed invasive adenocarcinomas of the intestine. When the radiosensitizer misonidazole was given in a single dose shortly before irradia...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1978.240

    authors: Rostom AY,Kauffman SL,Steel GG

    更新日期:1978-10-01 00:00:00

  • Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

    abstract:BACKGROUND:Here, we explore the therapeutic potential of dasatinib, a small-molecule inhibitor that targets multiple cytosolic and membrane-bound tyrosine kinases, including members of the Src kinase family, EphA2, and focal adhesion kinase for the treatment of ovarian cancer. METHODS:We examined the effects of dasati...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6605381

    authors: Konecny GE,Glas R,Dering J,Manivong K,Qi J,Finn RS,Yang GR,Hong KL,Ginther C,Winterhoff B,Gao G,Brugge J,Slamon DJ

    更新日期:2009-11-17 00:00:00

  • Survival of non-Western first generations immigrants with stomach cancer in North East Netherlands.

    abstract:BACKGROUND:Isolated groups, such as first generation non-Western immigrants, are at risk for suboptimal utilisation of the health care system resulting in a worse outcome. METHODS:From 1989 to 2007, all patients with stomach cancer were selected from the Comprehensive Cancer Centre North-East cancer registry. Associat...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.2011.64

    authors: Siemerink EJ,van der Aa MA,Siesling S,Hospers GA,Mulder NH

    更新日期:2011-03-29 00:00:00

  • Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.

    abstract::A serological assay for the quantitative determination of the novel tumour-associated epitope CA242 was developed and used for determination of sensitivity and specificity of CA242 in gastrointestinal cancer. The CA242 assay showed a better tumour specificity than CA50 (and CA 19-9). This was most noticeable in benign...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1992.44

    authors: Nilsson O,Johansson C,Glimelius B,Persson B,Nørgaard-Pedersen B,Andrén-Sandberg A,Lindholm L

    更新日期:1992-02-01 00:00:00

  • EpCAM (CD326) finding its role in cancer.

    abstract::Although epithelial cell adhesion/activating molecule (EpCAM/CD326) is one of the first tumour-associated antigens identified, it has never received the same level of attention as other target proteins for therapy of cancer. It is also striking that ever since its discovery in the late 1970s the actual contribution of...

    journal_title:British journal of cancer

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bjc.6603494

    authors: Baeuerle PA,Gires O

    更新日期:2007-02-12 00:00:00

  • Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy.

    abstract::The haemodynamics of the uterine arteries and myometrium were assessed using Doppler ultrasound in forty consecutive patients requiring treatment for invasive mole and choriocarcinoma. The investigations were performed prior to the commencement of chemotherapy and the subjects followed prospectively. The Doppler wavef...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1992.379

    authors: Long MG,Boultbee JE,Langley R,Newlands ES,Begent RH,Bagshawe KD

    更新日期:1992-11-01 00:00:00

  • A trial of chemotherapy in patients with osteosarcoma (a report to the Medical Research Council by their Working Party on Bone Sarcoma.

    abstract::Two hundred and thirty five patients with osteosarcoma, aged less than 40 years, and treated by amputation or radiotherapy, were entered in a randomised trial of two forms of adjuvant chemotherapy. A two drug regimen, namely vincristine 2 mg m-2 (maximum 2mg) followed by methotrexate 200 mgm-2, given every three weeks...

    journal_title:British journal of cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/bjc.1986.81

    authors:

    更新日期:1986-04-01 00:00:00

  • Cancer risk in Swedish women: the relation to size at birth.

    abstract::The relationship between fetal growth as indicated by weight and length at birth, and cancer risk in 1080 adult Swedish women was examined. Birth factors were retrieved from original midwife records for the years 1914, 1918, 1922 and 1930, and primary cancer cases were identified by matching with national and regional...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1054/bjoc.2000.1738

    authors: Andersson SW,Bengtsson C,Hallberg L,Lapidus L,Niklasson A,Wallgren A,Hulthén L

    更新日期:2001-05-04 00:00:00

  • Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies.

    abstract::Monoclonal antibodies to epithelial-cell antigenic determinants, labelled with 123I and 125I, were administered parenterally to immunodeficient mice bearing human tumours derived from a human cancer cell line. Anterior, posterior and lateral radioscans of the body were taken with a gamma scintillation camera at variou...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1982.157

    authors: Epenetos AA,Nimmon CC,Arklie J,Elliott AT,Hawkins LA,Knowles RW,Britton KE,Bodmer WF

    更新日期:1982-07-01 00:00:00

  • Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

    abstract:BACKGROUND:Alternative treatments are needed for elderly patients with acute myeloid leukaemia, as the disease prognosis is poor and the current treatment is unsuitable for many patients. METHODS:In this study, we investigated whether combining the nucleoside analogue sapacitabine with histone deacetylase (HDAC) inhib...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6605922

    authors: Green SR,Choudhary AK,Fleming IN

    更新日期:2010-10-26 00:00:00

  • Sigma-2 receptors as a biomarker of proliferation in solid tumours.

    abstract::Over the past several years, our group has provided considerable evidence that the expression of sigma-2 (sigma2) receptors may serve as a biomarker of tumour cell proliferation. In these in vitro studies, sigma2 receptors were expressed 8-10 times more in proliferative (P) tumour cells than in quiescent (Q) tumour ce...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1054/bjoc.1999.1067

    authors: Wheeler KT,Wang LM,Wallen CA,Childers SR,Cline JM,Keng PC,Mach RH

    更新日期:2000-03-01 00:00:00

  • Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma.

    abstract:BACKGROUND:Bcl-xL has an important role in the control of cell death through its inhibition of apoptosis. The aim of this study was to investigate the clinicopathological significance of Bcl-xL in upper urinary tract urothelial carcinoma (UTUC) and the therapeutic effect of targeting Bcl-xL protein in urothelial carcin...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.2013.216

    authors: Yoshimine S,Kikuchi E,Kosaka T,Mikami S,Miyajima A,Okada Y,Oya M

    更新日期:2013-06-11 00:00:00

  • Population-based cancer incidence in Sikkim, India: report on ethnic variation.

    abstract:BACKGROUND:A Population-Based Cancer Registry (PBCR) was set up in Sikkim (a state in the North Eastern India) in 2003. We examined incidence rates by ethnic groups from 2003-2008. METHODS:Age-adjusted incidence rates (AARs) per 100,000 person-years were calculated by direct method using the world standard population,...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.2011.598

    authors: Verma Y,Pradhan PK,Gurung N,Sapkota SD,Giri P,Sundas P,Bhattarai BN,Nadayil D,Ramnath T,Nandakumar A

    更新日期:2012-02-28 00:00:00

  • Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.

    abstract::Interleukin 6 (IL-6) and its soluble receptor (IL-6sR) can markedly stimulate aromatase activity in cultured fibroblasts derived from normal or malignant breast tissues. IL-6 acts by binding to a low-affinity membrane-spanning receptor (IL-6R), which must associate with a high-affinity receptor (gp130) for signal tran...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6600785

    authors: Purohit A,Singh A,Ghilchik MW,Serlupi-Crescenzi O,Reed MJ

    更新日期:2003-02-24 00:00:00

  • Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.

    abstract::The ribosome-inactivating proteins, bryodin, from Bryonia dioica, and momordin, from Momordica charantia, were coupled by a disulphide bond to a monoclonal anti-Thy 1.1 antibody (OX7). Both immunotoxins were specifically cytotoxic to the Thy 1.1-expressing mouse lymphoma cell line AKR-A in vitro. The OX7-bryodin immun...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1988.258

    authors: Stirpe F,Wawrzynczak EJ,Brown AN,Knyba RE,Watson GJ,Barbieri L,Thorpe PE

    更新日期:1988-11-01 00:00:00

  • Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases.

    abstract:BACKGROUND:Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial solid cancer. METHO...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/s41416-020-01254-0

    authors: Starzer AM,Steindl A,Mair MJ,Deischinger C,Simonovska A,Widhalm G,Gatterbauer B,Dieckmann K,Heller G,Preusser M,Berghoff AS

    更新日期:2021-01-21 00:00:00

  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).

    abstract:BACKGROUND:We investigated whether pazopanib maintenance following first-line chemotherapy would improve survival in patients with extensive disease small-cell lung cancer (ED-SCLC). METHODS:This study is a randomised, placebo-controlled, phase II study that enroled ED-SCLC patients who had not progressed after four c...

    journal_title:British journal of cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bjc.2017.465

    authors: Sun JM,Lee KH,Kim BS,Kim HG,Min YJ,Yi SY,Yun HJ,Jung SH,Lee SH,Ahn JS,Park K,Ahn MJ

    更新日期:2018-03-06 00:00:00

  • c-myc oncogene product expression and prognosis in operable breast cancer.

    abstract::The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient surv...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1989.337

    authors: Locker AP,Dowle CS,Ellis IO,Elston CW,Blamey RW,Sikora K,Evan G,Robins RA

    更新日期:1989-11-01 00:00:00

  • Somatic-cell hybrids producing antibodies against CEA.

    abstract::Monoclonal antibodies to carcinoembryonic antigen (CEA) promise improved specificity for the measurement of this widely expressed human cancer antigen. A mouse monoclonal antibody binds weakly to CEA in perchloric acid extracts of tumour but strongly to CEA similarly isolated from serum, and its spectrum of cancer det...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1981.1

    authors: Rogers GT,Rawlins GA,Bagshawe KD

    更新日期:1981-01-01 00:00:00

  • ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.

    abstract::The activity of ZD 1839 on brain metastases (BM) from Non-Small-Cell Lung Cancer (NSCLC) is unknown. We report four cases of BM responding to ZD 1839 theraphy. ...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6601116

    authors: Cappuzzo F,Calandri C,Bartolini S,Crinò L

    更新日期:2003-07-21 00:00:00

  • Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells.

    abstract::In vitro studies identified three Burkitts lymphoma cell lines, Ramos, MUTU-I and Daudi, that were growth inhibited by anti-IgM antibody. However, only Ramos and MUTU-I were sensitive to monoclonal antibodies (mAb) recognizing the Fc region of surface IgM (anti-Fc mu). Experiments using anti-Fc mu mAb (single or non-c...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6690136

    authors: Cragg MS,Zhang L,French RR,Glennie MJ

    更新日期:1999-02-01 00:00:00

  • Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.

    abstract:BACKGROUND:Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a pl...

    journal_title:British journal of cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bjc.2012.284

    authors: Fløtten Ø,Grønberg BH,Bremnes R,Amundsen T,Sundstrøm S,Rolke H,Hornslien K,Wentzel-Larsen T,Aasebø U,von Plessen C

    更新日期:2012-07-24 00:00:00

  • Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?

    abstract::Large primary breast tumours and extensive lymph node involvement are linked to a high rate of local recurrence after surgery. In 10-20% of such high-risk breast cancer patients, local relapse will occur despite postoperative radiotherapy. In the present study, we investigated whether molecular features, such as angio...

    journal_title:British journal of cancer

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bjc.6600755

    authors: Koukourakis MI,Giatromanolaki A,Galazios G,Sivridis E

    更新日期:2003-03-10 00:00:00

  • Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

    abstract::Supplementary Table 1 and the Supplementary Figure legends were not included when this manuscript was first published. The files are now available here. ...

    journal_title:British journal of cancer

    pub_type: 已发布勘误

    doi:10.1038/s41416-018-0130-x

    authors: Lièvre A,Ouine B,Canet J,Cartier A,Amar Y,Cacheux W,Mariani O,Guimbaud R,Selves J,Lecomte T,Guyetant S,Bieche I,Berger F,de Koning L

    更新日期:2018-08-01 00:00:00